Novogen drug acts on prostate cancer
Tuesday, 23 November, 2004
Novogen (ASX: NRT) subsidiary Marshall Edwards (LSE AIM: MSH, Nasdaq: MSHL) has reported that its lead drug phenoxodiol can slow down the progression of hormone refractory prostate cancer.
The results from a Phase Ib/IIa study of the drug in men with advanced metastatic disease were reported at the American Association of Cancer Research conference in Florida last week.
The dose response study showed that at the higher doses, the drug slowed the progression of disease and affected PSA levels over a period of 6-18 months, with no apparent toxicity, suggesting that the drug exerted an anti-tumour effect.
The company is planning a Phase IIb/IIIa multicentre international clinical trial to further test the drug in men with hormone refractory prostate cancer.
Stress during pregnancy could affect the baby's development
Maternal stress could leave epigenetic imprints on genes in the placenta associated with...
Bird flu detected at Victorian poultry farm
Agriculture Victoria has confirmed the presence of avian influenza at a poultry property in...
Common mouth and gut bacteria may increase stroke risk
A common bacteria usually found in the mouth and gastrointestinal tract appears to be abundant in...
